Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors

Current Medicinal Chemistry

Volumn 18, Issue 18, 2011, Pages 2686-2714

  Shuttleworth, S J ^a   Silva, F A ^a   Cecil, A R L ^a   Tomassi, C D ^a   Hill, T J ^a   Raynaud, F I ^b   Clarke, P A ^b   Workman, P ^b  

^a Southampton Science Park   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; Cardiovascular; Inflammation; Inhibitor; mTOR; p110 ; p110 ; p110 ; p110 ; PI3K

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; ANTINEOPLASTIC AGENT; AS 605340; CAL 101; CARBOPLATIN; GELDANAMYCIN; GSK 1059615; GSK 2126458; ISOENZYME; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PKI 179; PKI 567; PROTEIN P110; PWT 458; RAPAMYCIN; TG 100115; UNCLASSIFIED DRUG; UNINDEXED DRUG; WORTMANNIN; XL 147; XL 765;

ADVANCED CANCER; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; COWDEN SYNDROME; CRYSTAL STRUCTURE; DIARRHEA; DOSE RESPONSE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GLUCOSE BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; IC 50; INSULIN BLOOD LEVEL; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVARY CANCER; PATIENT SELECTION; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; URTICARIA; VOMITING;

CARDIOVASCULAR DISEASES; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; CLINICAL MEDICINE; HUMANS; INFLAMMATION; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 79959327886     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796011229     Document Type: Article

References (161)

1. Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev. Cancer, 2002, 2, 489-501. (Pubitemid 37328931)
2. Drees, B. E.; Mills, G. B.; Rommel, C.; Prestwich, G. D. Therapeutic potential of phosphoinositide 3-kinase inhibitors. Exp. Opin. Ther. Patents, 2004, 14, 703-732. (Pubitemid 38702329)
3. Workman, P.; Clarke, P. A.; Raynaud, F. I.; van Montfort, R. L. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res., 2010, 70, 2146-2157.
4. Shuttleworth, S.; Silva, F.; Tomassi, C.; Cecil, A.; Hill, T.; Rogers, H.; Townsend, P. In: Progress In Medicinal Chemistry; Lawton, Witty Ed. Elsevier Science B. V: 2009; Vol. 48, pp. 81-129.
5. Bjornsti, M. A.; Houghton, P. J. The TOR Pathway: A target for cancer therapy. Nat. Rev. Cancer, 2004, 4, 335-348. (Pubitemid 38579480)
6. Guertin, D. A.; Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell, 2007, 12, 9-22. (Pubitemid 47001784)
7. Stein, R. C.; Waterfield, M. D. PI3-kinase inhibition: a target for drug development? Mol. Med. Today, 2000, 6, 347-358.
8. Ihle, N. T.; Powis, G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol. Cancer Ther, 2009, 8, 1-9.
9. Chalhoub, N.; Baker, S. J. PTEN and the PI3-Kinase Pathway in Cancer. Ann. Rev. Pathol. Mech. Disease, 2009, 4, 127-150.
10. Samuels, Y.; Diaz, L. A. Jr.; Schmidt-Kittler, O.; Cummins, J. M.; Delong, L.; Cheong, I.; Rago, C.; Huso, D. L.; Lengauer, C.; Kinzler, K. W. Vogelstein, B.; Velculescu, V. E. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell, 2005, 7, 561-573. (Pubitemid 40799249)
11. Vogt, P.; Gymnopolous, M.; Hart, J. R. PI 3-kinase and cancer: changing accents. Curr. Opin. Genetics and Dev, 2009, 19, 1-6.
12. Wee, S.; Wiederschain, D.; Maira, S. M.; Loo, A.; Miller, C.; DeBeaumont, R. Stegmeier, F.; Yao, Y. M.; Lengauer, C. PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. USA, 2008, 105, 13057-13062.
13. Jia, S.; Roberts, T. M.; Zhao, J. J. Should individual PI3 kinase isoforms be targeted in cancer? Curr. Opin. Cell. Biol, 2009, 21, 199-208.
14. Billottet, C.; Grandage, V. L.; Gale, R. E.; Quattropani, A.; Rommel, C.; Vanhaesebroeck, B.; Khwaja, A. A selective inhibitor of the p1 108 isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene, 2006, 25, 6648-6659. (Pubitemid 44646192)
15. Cornillet-Lefebvre, P.; Cuccuini, W.; Bardet, V.; Tamburini, J.; Gillot, L.; Ifrah, N.; Nguyen, P.; Dreyfus, F.; Mayeux, P.; Lacombe, C.; Bouscary, D. Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p1 10δ mutations. Leukemia, 2006, 20, 374-376. (Pubitemid 43148686)
16. Jackson, S. P.; Schoenwaelder, S. M.; Goncalves, I.; Nesbitt, W. S.; Yap, C. L.; Wright, C. E.; Kenche, V.; Anderson, K. E.; Dopheide, S. M.; Yuan, Y.; Sturgeon, S. A.; Prabaharan, H.; Thompson, P. E.; Smith, G. D.; Shepherd, P. R.; Daniele, N.; Kulkarni, S.; Abbott, B.; Saylik, D.; Jones, C.; Lu, L.; Giuliano, S.; Hughan, S. C.; Angus, J. A.; Robertson, A. D.; Salem, H. H. PI 3-kinase p110β: a new target for antithrombotic therapy. Nature Med., 2005, 11, 507-514. (Pubitemid 40685973)
17. Utsugi, M.; Dobashi, K.; Ono, A.; Ishizuka, T.; Matsuzaki, S.; Hisada, T.; Shimizu, Y.; Kawata, T.; Aoki, H.; Kamide, Y.; Mori, M. PI3K p110β Positively Regulates Lipopolysaccharide-Induced IL-12 Production in human macrophages and dendritic cells and JNK1 plays a novel role. J. Immunol, 2009, 182, 5225-5231.
18. Windmiller, D. A.; Backer, J. M. Distinct phosphoinositide 3-kinases mediate mast cell degranulation in response to G-protein-coupled versus FcepsilonRI receptors. J. Biol. Chem., 2003, 278, 11874-11878. (Pubitemid 36800158)
19. Boyle, K. B.; Gyori, D.; Sindrilaru, A.; Scharffetter-Kochanek, K.; Taylor, P. R.; Mócsai, A.; Stephens, L. R.; Hawkins, P. T. Class IA Phosphoinositide 3-Kinase β amd δ Regulated Neutrophil Oxidase Activation in Response to Aspergillus fumigatus Hyphae. J. Immunol, 2011, 186(5), 2978-2989.
20. Rommel, C.; Camps, M.; Ji, H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nature Rev. Immunol, 2007, 7, 191-201.
21. Walker, E. H.; Perisic, O.; Ried, C.; Stephens, L.; Williams, R. L. Structural insights into phosphoinositide 3-kinase catalysis and signalling. Nature (London), 1999, 402, 313-320. (Pubitemid 129516270)
22. Ali, K.; Bilancio, A.; Thomas, M.; Pearce, W.; Gilfillan, A. M.; Tkaczyk, C.; Kuehn, N.; Gray, A.; Giddings, J.; Peskett, E.; Fox, R.; Bruce, I.; Walker, C.; Sawyer, C.; Okkenhaug, K.; Finan, P. and Vanhaesebroeck, B. Essential role for the p110δ phosphoinositide 3-kinase in the allergic response. Nature (London), 2004, 431, 1007-1011. (Pubitemid 39434424)
23. Rückle, T.; Schwarz, M. K.; Rommel, C. PI3Ky inhibition: towards an aspirin of the 21st century? Nature Rev. Drug Discov, 2006, 5, 903-918.
24. Park, S. J.; Lee, K. S.; Kim, S. R.; Min, K. H.; Moon, H.; Lee, M. H.; Chung, C. R.; Han, H. J.; Puri, K. D.; Lee, Y. C. Phosphoinositide 3-kinase 8 inhibitor suppresses IL-17 expression in a murine asthma model. Eur. Respir. J., 2010, 36, e-pub ahead of print.
25. Berndt; A.; Miller, S.; Williams, O.; Le, D. D.; Houseman, B. T.; Pacold, J. I.; Gorrec, F.; Hon, W. C.; Liu, Y.; Rommel, C.; Gaillard, P.; Rückle, T.; Schwarz, M. K.; Shokat, K. M.; Shaw, J. P.; Williams, R. L. The p110δ structure: mechanisms for selectivity and potency of new PI (3) K inhibitors. Nature Chem. Biol, 2010, 6, 117-124.
26. Shuttleworth, S.; Silva, F.; Tomassi, C.; Cecil, A.; Hill, T.; Rogers, H.; Townsend, P. In: Progress In Medicinal Chemistry; Lawton, Witty Ed. Elsevier Science B. V: 2011; Vol. 50, pp. 109-133.
27. Brazelton, T. R.; Morris, R. E. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr. Opin. Immunol, 1996, 8, 710-720. (Pubitemid 26385402)
28. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran-4-one (LY294002). J. Biol. Chem., 1994, 269, 5241-5248.
29. Kong, D.; Yamori, T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci., 2008, 99, 1734-1740.
30. Maira, S. M.; Stauffer, F.; Schnell, C.; García-Echeverria, C. PI3K inhibitors for cancer treatment: where do we stand? Biochem. Soc. Trans., 2009, 37, 265-272.
31. Ihle, N. T.; Powis, G. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Molecular Asp. Med, 2010, 31, 135-44.
32. Ito, K.; Caramori, G.; Adcock, I. M. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J. Pharmacol. Exp. Ther, 2007, 321, 1-8. (Pubitemid 46456952)
33. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J. A.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The identification of 2-(1H-indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3, 2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 2008, 51, 5522-5532.
34. Raynaud, F. I.; Eccles, S. A.; Patel, S.; Alix, S.; Box, G.; Chuckowree, I.; Folkes, A.; Gowan, S.; De Haven-Brandon, A.; Di Stefano, F.; Hayes, A.; Henley, A. T.; Lensun, L.; Pergl-Wilson, G.; Robson, A.; Saghir, N.; Zhyvoloup, A. McDonald, E.; Sheldrake, P.; Shuttleworth, S.; Valenti, M.; Wan, N. C.; Clarke, P. A.; Workman, P. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Can. Ther., 2009, 8, 1725-1738.
35. Gale, S.; Croasdell, G. 28th Annual JPMorgan Healthcare Conference-Exelixis and Nektar Therapeutics. iDrugs, 2010, 13, 139-141.
36. Knight, S. D.; Adams, N. D.; Burgess, J. L.; Chaudhari, A. M.; Darcy, M. G.; Donatelli, C. A.; Luengo, J. I.; Newlander, K. A.; Parrish, C. A.; Ridgers, L. H.; Sarpong, M. A.; Schmidt, S. J.; Van Aller, G. S.; Carson, J. D.; Diamond, M. A.; Elkins, P. A.; Gardiner, C. M.; Garver, E.; Gilbert, S. A.; Gontarek, R. R.; Jackson, J. R.; Kershner, K. L.; Luo, L.; Raha, K.; Sherk, C. S.; Sung, C. M.; Sutton, D.; Tummino, P. J.; Wegrzyn, R. J.; Auger, K. R.; Dhanak, D. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med. Chem. Lett., 2010, 1, 39-43.
37. Kong, D.; Yamori, T. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci., 2007, 98, 1638-1642. (Pubitemid 47308463)
38. Herman, S. E.; Gordon, A. L.; Wagner, A. J.; Heerema, N. A.; Zhao, W.; Flynn, J. M.; Jones, J.; Andritsos, L.; Puri, K. D.; Lannutti, B. J.; Giese, N. A.; Zhang, X.; Wei, L.; Byrd, J. C.; Johnson, A. J. Phosphatidylinositol 3-kinase-8 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood, 2010, 116, 2078-2088.
39. Garlich, J. R.; De, P.; Dey, N.; Su, J.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G. B.; Kundra, V.; Shu, H. K.; Peng, Q. and Durden, D. L. Experimental therapeutics, molecular targets, and chemical biology: a vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumour and antiangiogenic activity. Cancer Res., 2008, 68, 206-215. (Pubitemid 351380122)
40. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual PI3K/mTor inhibitor with potent in vivo antitumour activity. Mol Cancer Ther., 2008, 7, 1851-1863.
41. Molckovsky, A.; Siu, L. L. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J. Hematol. Oncol, 2008, 1, 20.
42. Robertson, A. D.; Jackson, S.; Kenche, A.; Yaip, C.; Parbaharan, H. and Thompson, P. Therapeutic morpholino-substituted compounds. PCT Int. Appl., WO 2001/53266, July 26, 2001.
43. Chiosis, G.; Rosen, N.; Sepp-Lorenzino, L. LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg. Med. Chem. Lett, 2001, 11, 909-913. (Pubitemid 32226213)
44. Zask, A.; Kaplan, J.; Toral-Barza, L.; Hollander, I.; Young, M.; Tischler, M.; Gaydos, C.; Cinque, M.; Lucas, J. and Yu, K. Synthesis and Structure-Activity Relationships of Ring-Opened 17-Hydroxywortmannins: Potent Phosphoinositide 3-Kinase Inhibitors with Improved Properties and Anticancer Efficacy. J. Med. Chem., 2008, 51, 1319-1323. (Pubitemid 351480392)
45. Zhu, T.; Gu, J.; Yu, K.; Lucas, J.; Cai, P.; Tsao, R.; Gong, Y.; Li, F.; Chaudhary, I.; Desai, P.; Ruppen, M.; Fawzi, M.; Gibbons, J.; Ayral-Kaloustian, S.; Skotnicki, J.; Mansour, T.; Zask, A. Pegylated wortmannin and 17-hydroxywortmannin conjugates as phosphoinositide 3-kinase inhibitors active in human tumour xenograft models. J. Med. Chem., 2006, 49, 1373-1378. (Pubitemid 43271889)
46. Hayakawa, M.; Kaizawa, H.; Moritomo, H.; Koizumi, T.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.; Raynaud, F. I.; Workman, P. Waterfield, M. Parker, P. Synthesis and biological evaluation of pyrido[3', 2':4, 5]furo[3, 2-d]pyrimidine derivatives as novel PI3 kinase p1 10α inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 2438-2442. (Pubitemid 46507793)
47. Hayakawa, M.; Kawaguchi, K. I.; Kaizawa, H.; Tomonobu, K.; Ohishi, T.; Yamano, M.; Okada, M.; Ohta, M.; Tsukamoto, S.; Raynaud, F. I.; Parker, P.; Workman, P.; Waterfield, M. D. Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1, 2-a]pyridines as novel PI3 kinase p1 10α inhibitors. Bioorg. Med. Chem., 2007, 15, 5837-5844. (Pubitemid 47043472)
48. Kendall, J. D.; Rewcastle, G. W.; Frederick, R.; Mawson, C.; Denny, W. A.; Marshall, E. S.; Baguley, B. C.; Chaussade, C.; Jackson, S. P.; Shepherd, P. R. Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p1 10 alpha inhibitors. Bioorg. Med. Chem., 2007, 15, 7677-7687. (Pubitemid 47575920)
49. Alexander, R.; Balasundaram, A.; Batchelor, M.; Brookings, D.; Crepy, K.; Crabbe, T.; Deltent, M. F.; Driessens, F.; Gill, A.; Harris, S.; Hutchinson, G.; Kulisa, C.; Merriman, M.; Mistry, P.; Parton, T.; Turner, J.; Whitcombe, I.; Wright, S. 4-(1, 3-Thiazol-2-yl) morpholine derivatives as inhibitors of phosphoinositide 3-kinase. Bioorg. Med. Chem. Lett, 2008, 18, 4316-4320.
50. Capraro, H.-G.; Carvatti, G.; Furet, P.; Imbach, P.; Lan, J.; Pecchi, S.; Schoepfer, J. 3, 6-Distubstituted-imidazo [1, 2-b] pyrazines and 3, 5-disubstituted pyrazolo[1, 5-a] pyrimidines as phosphatidylinositol-3-kinase inhibitors. PCT Int. Appl., WO 2008/138889, November 20, 2008.
51. Aspel, B.; Blair, J. A.; Gonzalez, B.; Nazif, T. M.; Feldman, M. E.; Aizenstein, B.; Hoffman, R.; Wiliams, R. L.; Shokat, K. M.; Knight, Z. A. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nature Chem. Biol, 2008, 4, 691-699.
52. Zask, A.; Nowak, P. W.; Verheijen, J.; Curran, K. J.; Kaplan, J.; Malwitz, D.; Bursavich, M. G.; Cole, D. C.; Ayral-Kaloustian, S.; Yu, K.; Richard, D. J.; Lefever, M. Pyrazolpyrimidine analogues and their use as mTOR kinase and PI3 kinase inhibitors. PCT Int. Appl., WO 2008/115974, September 25, 2008
53. Booker, S.; D'Angelo, N.; D'Amico, D. C.; Kim, T.; Liu, L.; Meagher, K.; Norman, M. H.; Panter, K.; Schenkel, L. B.; Smith, A.; Tamayo, N.; Whittington, D. A.; Xi, N.; Yang, K. PI3 kinase modulators and methods of use. PCT Int. Appl., WO 2009/017822, February 5, 2009.
54. Cheng, H.; Bhumralkar, D.; Dress, K. R.; Hoffman, J. E.; Johnson, M. C.; Kania, R. S.; Le, P. T. Q., Nambu, M. D.; Pairish, M. A.; Plewe, M. B.; Tran, K. T. Pyrido (2, 3-d) pyrimidone compounds and their use as PI3 inhibitors. PCT Int. Appl., WO 2008/032162, March 20, 2008.
55. White, S. L.; Kesicki, E. A.; Thorsett, E. A.; Ruan, F.; Farouz, F. Thienpyrimidines for treatment of inflammatory disorders and cancers. PCT Int. Appl., WO 2008/064018, May 29, 2008.
56. Perry, B.; Alexander, R.; Bennett, G.; Buckley, G.; Ceska, T.; Crabbe, T.; Dale, V.; Gowers, L.; Horsley, H.; James, L.; Jenkins, K.; Crepy, K.; Kulisa, C.; Lightfoot, H.; Lock, C.; Mack, S.; Morgan, T.; Nicolas, A. L.; Pitt, W.; Sabin, V.; Wright, S. Achieving multi-isoform PI3K inhibition in a series of substituted 3, 4-dihydro-2H-benzo[1, 4]oxazines. Bioorg. Med. Chem. Lett, 2008, 18, 4700-4704.
57. Camps, M.; Ruckle, T.; Ji, H.; Ardissone, V.; Rintelen, F.; Shaw, J.; Ferrandi, C.; Chabert, C.; Gillieron, C.; Francon, B.; Martin, T.; Gretener, D.; Perrin, D.; Leroy, D.; Vitte, P. A.; Hirsch, E.; Wymann, M. P.; Cirillo, R.; Schwarz, M. K.; Rommel, C. Blockade of PI3K gamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nature Med, 2005, 11, 936-943. (Pubitemid 41294438)
58. Quattropani, A.; Rueckle, T.; Schwarz, M.; Dorbais, J.; Sauer, W.; Cleva, C.; Desforges, G. Thiazole derivatives and their use thereof. PCT Int. Appl., WO 2005/068444, July 28, 2005.
59. Bruce, I.; Finan, P.; Leblanc, C.; McCarthy, C.; Whitehead, L.; Blair, N. E.; Bloomfield, F. C.; Hayler, J.; Kirman, L.; Oza, M. S.; Shukla, L. 5-Phenylthiazole derivatives and use as PI3 kinase inhibitors. PCT Int. Appl., WO 2003/072557, September 4, 2003.
60. Barvian, N. C.; Kolz, C. N.; Para, K. S.; Patt, W. C.; Visnick, M. Benzoxazin-3-ones and derivatives thereof as inhibitors of PI3K. PCT Int. Appl., WO 2004/052373, June 24, 2004.
61. Connolly, M. K.; Gogliotti, R. D.; Lee, H. T.; Plummer, M. S.; Sexton, K. E.; Visnick, M. Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents. PCT Int. Appl., WO 2004/108713, December 16, 2004.
62. Yuan, H.; Pupo, M. T.; Blois, J.; Smith, A.; Weissleder, R.; Clardy, J.; Josephson, L. A stabilized demethoxyviridin derivative inhibits PI3 kinase. Bioorg. Med. Chem. Lett, 2009, 19, 4223-4227.
63. Frederick, R.; Mawson, C.; Kendall, J. D.; Chaussade, C.; Rewcastle, G. W.; Shepherd, P. R.; Denny, W. A. Phosphoinositide-3-kinase (PI3K) inhibitors: identification of new scaffolds using virtual screening. Bioorg. Med. Chem. Lett, 2009, 19, 5842-5847.
64. Gilbert, A. M.; Nowak, P.; Brooijmans, N.; Bursavich, M. G.; Dehnhardt, C.; Delos Santos, E.; Feldberg, L. R.; Hollander, I.; Kim, S.; Lombardi, S.; Park, K.; Venkatesan, A. M.; Mallon, R. Novel purine and pyrazolo[3, 4-d]pyrimidine inhibitors of PI3 kinase-alpha: hit to lead studies. Bioorg. Med. Chem. Lett, 2010, 20, 636-639.
65. Venkatesan, A. M.; Dehnhardt, C. M.; Chen, Z. C.; Delos Santos, E.; Dos Santos, O.; Bursavich, M.; Gilbert, A. M.; Ellingboe, J. W.; Ayral-Kaloustian, S.; Khafizova, G.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Gibbons, J.; Abraham, R.; Mansour, T. S. Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors. Bioorg. Med. Chem. Lett, 2010, 20, 653-656.
66. Venkatesan, A. M.; Dehnhardt, C. M.; Santos, E. D.; Chen, Z.; Dos Santos, O.; Ayral-Kaloustian, S.; Khafizova, G.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Gibbons, J.; Abraham, R. T.; Chaudhary, I.; Mansour, T. S. Bis (morpholino-1, 3, 5-triazine) Derivatives: Potent Adenosine 50-Triphosphate Competitive Phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J. Med. Chem., 2010, 53, 2636-2645.
67. Venkatesan, A. M.; Chen, Z.; Dos Santos, O.; Dehnhardt, C.; Delos Santos, E.; Ayral-Kaloustian, S.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Yu, K.; Chaudhary, I.; Mansour, T. S. PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. Bioorg. Med. Chem. Lett, 2010, 20, 5869-5873.
68. Chen, Z.; Venkatesan, A. M.; Dos Santos, O.; Santos, E. D.; Dehnhardt, C. M.; Ayral-Kaloustian, S.; Ashcroft, J.; McDonald, L. A.; Mansour, T. S. Stereoselective Synthesis of an active metabolite of the potent PI3 kinase inhibitor PKI-179. J. Org. Chem., 2010, 75, 1643-1651.
69. Dehnhardt, C. M.; Venkatesan, A. M.; Santos, E. D.; Chen, Z.; Santos, O.; Kaloustian, S. A.; Brooijmans, N.; Mallon, R.; Hollander, I.; Feldberg, L.; Lucas, J.; Chaudhary, I.; Yu, K.; Gibbons, J.; Abraham, R.; Mansour, T. S. Lead optimization of N-3-substituted 7-moroholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: Discovery of PKI-402. J. Med Chem., 2010, 53, 798-810.
70. Zhang, N.; Ayral-Kaloustian, S.; Anderson, J. T., Nguyen, T.; Das, S.; Venkatesan, A. M.; Brooijmans, N.; Lucas, J.; Yu, K.; Hollander, I.; Mallon, R. 5-Ureidobenzofuranone indoles as potent and efficacious inhibitors of PI3-kinase a and mTOR for the treatment of breast cancer. Bioorg. Med. Chem. Lett, 2010, 20, 3526-3529.
71. Venkatesan, A. M.; Chen, Z.; Dos Santos, O.; Brooijmans, N.; Gopalsamy, A. 7H-pyrrolo[2, 3-H]quinazoline compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their synthesis. PCT Int. Appl., WO 2009/111547, September 11, 2009.
72. Chen, Z.; Venkatesan, A. M.; Dehnhardt, C. M.; Ayral-Kaloustian, S.; Brooijmans, N.; Mallon, R.; Feldberg, L.; Hollander, I.; Lucas, J.; Yu, K.; Kong, F.; Mansour, T. S. Synthesis and SAR of Novel 4- Morpholinopyrrolopyrimidine Derivatives as Potent Phosphatidylinositol 3-Kinase Inhibitors. J. Med. Chem., 2010, 53, 3169-3182.
73. Chen, Z.; Venkatesan, A. M.; Zask, A.; Verheijen, J. C.; Ayral-Kaloustian, S.; Mansour, T. S.; Curran, K. J. (2-Aryl-7H-pyrrolo[2, 3-d]pyridimidin-4-yl) morpholine compounds, their use as mTOR kinase and PI3 kinase inhibitors, and their sytheses. PCT Int. Appl., WO 2010/002954, January 7, 2010
74. Montagne, C.; Bombrum, A.; Desforges, G.; Quattropani, A.; Gaillard, P. 2-Morpholino-pyrido[3, 2-d]pyrimidines. PCT Int. Pat. Appl., WO 2010/091996, August 19, 2010.
75. Cardin, D. P.; Gaulin, J. L.; Greenspan, P. D.; Vyskocil, S.; Xu, T.; Renou, C. C. Thiophene or thiazole derivatives and their use a PI3K inhibitors. PCT Int. Pat. Appl., WO 2009/154741, December 23, 2009.
76. Renou, C. C. Thiophenes and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors. PCT Int. Pat. Appl., WO 2009/094224, July 30, 2009.
77. Bo, Y. Y.; Booker, S.; Bryan, M.; Deak, H. L.; Liu, L.; Andrews, K.; Nishimura, N.; Norma, M. H.; Panter, K.; Schenkel, L.; Siegmund, A. C.; Tamayo, N. A.; Yang, K. Inhibitors of PI3 Kinase. PCT Int. Pat. Appl., WO 2009/155121, December 23, 2009.
78. Boezio, A.; Cheng, A. C.; Coats, J. R.; Copeland, K. W.; Graceffa, R.; Harmange, J.-C.; Huang, H.; La, D.; Olivieri, P. R.; Peterson, E. A.; Schenkel, L. Indole/benzimidazole compounds as mTOR kinase inhibitors. PCT Int. Pat. Appl., WO 2010/096314, August 26, 2010.
79. Bo, Y. Y.; Liu, L.; Nishimura, N.; Norman, M. H.; Siegmund, A. C.; Tamayo, N. A.; Yang, K. Inhibitors of PI3 kinase. PCT Int. Pat. Appl., WO 2010/108074, July 23, 2010.
80. Rewcastle, G. W.; Shepherd, P. R.; Chaussade, C.; Denny, W. A., Gamage, S. A. Substituted pyrimidines and triazines and their use in cancer therapy. PCT Int. Pat. Appl., WO 2009/120094, October 1, 2009.
81. Heffron, T. P.; Berry, M.; Castanedo, G.; Chang, C.; Chuckowree, I.; Dotson, J.; Folkes, A.; Gunzner, J.; Lesnick, J. D.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Peterson, D.; Salphati, L.; Sampath, D.; Sideris, S.; Sutherlin, D. P.; Tsui, V.; Wan, N. C.; Wang, S.; Wong, S.; Zhu, B.-Y. Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor. Bioorg. Med. Chem. Lett., 2010, 20, 2408-2411.
82. Cai, X.; Zhai, H.; Lai, C.-J.; Qian, C. Phosphoinositide-3-kinase inhibitors with a zinc binding moiety. PCT Int. Pat. Appl., WO 2010/080996, July 15, 2010
83. Baik, T.-G.; Ma, S.; Buhr, C. A.; Nuss, J. M. Pyridopyrimidinone inhibitors of PI3K and mTOR. PCT Int. Pat. Appl., WO 2010/039740, April 8, 2010.
84. Cheng, H.; Bagrodia, S.; Bailey, S.; Edwards, M.; Hoffman, J.; Hu, Q.; Kania, R.; Knighton, D. R.; Marx, M. A.; Ninkovic, S.; Sun, S.; Zhang, E. Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. Med. Chem. Commun., 2010, 1, 139-144.
85. Fairhurst, R. A.; Imbach, P. Organic compounds. PCT Int. Pat. Appl., WO 2009/080705, July 2, 2009.
86. Caravetti, G.; Fairhurst, R. A.; Furet, P.; Guagnano, V.; Imbach, P. Organic compounds. PCT Int. Pat. Appl., WO 2010/029082, March 18, 2010.
87. Kim, D.; Jun, H.; Lee, H.; Hong, S. S.; Hong, S. Development of New Fluorescent Xanthines as Kinase Inhibitors. Org. Lett, 2010, 12, 1212-1215.
88. Cheng, H.; Johnson, T. W.; Hoffman, J. E.; Guo, L. C.; Liu, Z.; Johnson, T. O.; Liu, K. K. C. Imidazo[1, 5]naphthyridine compounds, their pharmaceutical use and compositions. PCT Int. Pat. Appl., WO 2010/038165, April 8, 2010.
89. Lee, C. H. A.; Nagaraj, H. K. M.; William, A. D.; Williams, M.; Xiang, Z. Triazine compounds as kinase inhibitors. PCT Int. Pat. Appl., WO 2009/093981, July 30, 2009.
90. Nagaraj, H. K. M.; Williams, M.; Soh, C. K. Pyrazine substituted purines. PCT Int. Pat. Appl., WO 2009/157880, December 30, 2009.
91. Morales, G. A.; Weber, K. T.; Newblom, J. M.; Peng, X.; Su, J.; Garlich, J. R. Thienopyranones as kinase inhibitors. PCT Int. Pat. Appl., WO 2009/094560, July 30, 2009.
92. Staben, S. T.; Heffron, T. P.; Sutherlin, D. P.; Bhat, S. R.; Castanedo, G. M.; Chuckowree, I. S.; Dotson, J.; Folkes, A. J.; Friedman, L. S.; Lee, L.; Lesnick, J.; Lewis, C.; Murray, J. M., Nonomiya, J.; Olivero, A. G.; Plise, E.; Pang, J.; Prior, W. W.; Salphati, L.; Rouge, L.; Sampath, D.; Tsui, V.; Wan, N. C.; Wang, S.; Weismann, C.; Wu, P.; Zhu, B.-Y. Structure-based optimization of pyrazolo-pyrimidine and-pyridine inhibitors of PI3-kinase. Bioorg. Med. Chem. Lett., 2010, 20, 6048-6051.
93. Large, J. M.; Torr, J. E.; Raynaud, F. I.; Clarke, P. A.; Hayes, A.; di Stefano, F.; Urban, F.; Shuttleworth, S. J.; Saghir, N.; Sheldrake, P.; Workman, P.; McDonald, E. Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors. 3-Hydroxyphenol analogues and bioisosteric replacements. Bioorg. Med. Chem., 2011, 19, 836-851.
94. Fjellström, O.; Gustafsson, D.; Jackson, S.; Lundberg, J. Å. Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl) 4-oxo-4H-pyrido [1, 2-a]pyrimidin-9-yl) ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it. PCT Int. Pat. Appl., WO 2009/093972, July 30, 2009.
95. Henteman, M. F.; Scott, W.; Wood, J.; Johnson, J.; Redman, A.; Bullion, A.-M.; Guernon, L. Sulfone substituted 2, 3-dihydroimidazo[1, 2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis. PCT Int. Pat., 2009, WO 2009/091550, July 23, 2009.
96. Ramsden, N.; Bell, K.; Cansfield, A.; Taylor, J.; Sunose, M.; Middlemiss, D. 2-Aminoimidazo[1, 2-b]pyridazine derivatives as PI3K inhibitors. PCT Int. Pat. Appl., WO 2010/007099, January 21, 2010.
97. Ramsden, N.; Bell, K.; Cansfield, A.; Taylor, J.; Sunose, M.; Middlemiss, D.; Ellard, K. 7-Substituted amino triazoles as PI3K inhibitors. PCT Int. Pat. Appl., WO 2010/007100, January 21, 2010.
98. Ramsden, N.; Bell, K.; Taylor, J.; Sunose, M.; Middlemiss, D.; Ellard, K. Urea triazololo[1, 5-a]pyridine derivatives as PI3K inhibitors. PCT Int. Pat. Appl., WO 2010/092015, August 19, 2010.
99. Ren, P.; Liu, Y.; Li, L.; Chan, K.; Wilson, T. E. Benzothiazole kinase inhibitors and methods of use. PCT Int. Pat. Appl., WO 2009/114874, September 17, 2009.
100. Ren, P.; Liu, Y.; Li, L.; Chan, K.; Wilson, T. E. Heterocyclic Kinase inhibitors. PCT Int. Pat. Appl., WO 2010/036380, April 1 2010.
101. Swinnen, D.; Jorand-Lebrun, C.; Grippi-Vallotton, T.; Gerber, P.; Gonzalez, J.; Shaw, J. P. Fused bicyclic compounds and the use thereof as PI3K inhibitors. PCT Int. Pat. Appl., WO 2009/133127, May 11, 2009.
102. Swinnen, D.; Jorand-Lebrun, C.; Grippi-Vallotton, T.; Gerber, P.; Gonzalez, J.; Shaw, J. P.; Jeyaprakashnaryanan, S. Fused bicyclic compounds as inhibitors for PI3 kinase. PCT Int. Pat. Appl., WO 2010/100144, September 10, 2010.
103. Pomel, V.; Gaillard, P. Desforges, G.; Quattropani, A.; Montagne, C. 4-Morpholino-pyrido[3, 2-d]pyrimidines. PCT Int. Pat. Appl., WO 2010/037765, August 4, 2010.
104. Wang, T.; Aronov, S.; Cornebise, M.; Maltais, F.; Ledeboer, M.; Le Tiran, A.; Marone, V.; Messersmith, D.; Cottrelli, K. Inhibitors of phosphatidylinositol 3-kinase. PCT Int. Pat. Appl., WO 2009/12911, October 22, 2009.
105. Bruce, I.; Budd, E.; Edwards, L.; Howsham, C. Organic compounds. PCT Int. Pat. Appl., WO 2009/115517, September 24, 2009.
106. Knight, Z. A.; Gonzalez, B.; Feldman, M. E.; Zunder, E. R.; Goldenberg, D. D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W. A.; Williams, R. L.; Shokat, K. M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signalling. Cell, 2006, 125, 733-747.
107. Knight, Z. A. Small molecule inhibitors of the PI3-kinase family. Curr. Top. Microbiol. Immunol., 2010, 347, 263-278.
108. Yap, T. A.; Sandhu, S. K.; Workman, P.; de Bono, J. S. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer, 2010, 10, 514-523.
109. Coughlin, C. M.; Johnston, D. S.; Strahs, A.; Burczynski, M. E.; Bacus, S.; Hill, J.; Feingold, J. M.; Zacharchuk, C.; Berkenblit, A. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy. Breast Cancer Res. Treat., 2010, 124, 1-11.
110. Andersen, J. N.; Sathyanarayanan, S.; Di Bacco, A.; Chi, A.; Zhang, T.; Chen, A. H.; Dolinski, B.; Kraus, M.; Roberts, B.; Arthur, W.; Klinghoffer, R. A.; Gargano, D.; Li, L.; Feldman, I.; Lynch, B.; Rush, J.; Hendrickson, R. C.; Blume-Jensen, P.; Paweletz, C. P. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci. Transl. Med., 2010, 2, 43-55.
111. Guillard, S.; Clarke, P. A.; Te Poele, R.; Mohri, Z.; Bjerke, L.; Valenti, M.; Raynaud, F.; Eccles, S. A.; Workman, P. Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell Cycle, 2009, 8, 443-453.
112. Sarker, D.; Clarke, P. A.; Welsh, L.; Raynaud, F.; Valenti, M.; Tandy, D.; Titley, I.; Eccles, S.; Garrett, M.; Workman, P. Use of gene expression microarrays to identify novel pharmacodynamic biomarkers of phosphatidylinositide-3'-kinase (PI3K) inhibition. Proc. AACR Meeting Abstracts, 2008, abstr. 3614.
113. Williams, R.; Baker, A. F.; Ihle, N. T.; Winkler, A. R.; Kirkpatrick, L.; Powis, G. The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signalling. Cancer Chemother. Pharmacol., 2006, 58, 444-450. (Pubitemid 43999792)
114. Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P. J.; Valero, V.; Guzman, M.; Botero, M. L.; Llonch, E.; Atzori, F.; Di Cosimo, S.; Maira, M.; Garcia-Echeverria, C.; Parra, J. L.; Arribas, J.; Baselga, J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signalling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res., 2008, 68, 8022-8030.
115. Markman, B.; LoRusso, P. M.; Patnaik, A.; Heath, E.; Laird, A. D.; van Leeuwen, B. A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumours. Eur. J. Cancer, 2008, 6, 216.
116. Baselga, J.; De Jonge, M. J.; Rodon, J.; Burris III, H. A.; Birle, D. C.; De Buck, S. S.; Demanse, D.; Ru, Q. C.; Goldbrunner, M.; Bendell, J. C. A firstin-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumours. J. Clin. Oncol. (ASCO Meeting Abstracts), 2010, 28, 3003.
117. Baird, R. D.; Kristeleit, R. S.; Sarker, D.; Olmos, D.; Sandhu, S. K.; Yan, Y.; Koeppen, H.; Levy, G. G.; Jin, J.; De Bono, J. S. A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral panphosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. J. Clin. Oncol. (ASCO Meeting Abstracts), 2010, 28, 2613.
118. Von Hoff, D. D.; LoRusso, P.; Tibes, R.; Shapiro, G.; Weiss, G. J.; Ware, J. A.; Fredrickson, J.; Mazina, K. E.; Levy, G. G.; Wagner, A. J. A first-inhuman phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumours. J. Clin. Oncol. (ASCO Meeting Abstracts), 2010, 28, 2541.
119. Soria, J. C.; Gomez-Roca, C. A.; Ware, J. A.; Adjei, A. A.; Brachmann, R. K.; Groen, H. J. M. A Phase Ib study to evaluate the pan-PI3K inhibitor GDC-0941 with paclitaxel and carboplatin with and without bevacizumab in nonsmall cell lung cancer patients. Eur. J. Cancer, 2010, 8, 421.
120. Dolly, S.; Wagner, A. J.; Bendell, J. C.; Yan, Y.; Ware, J. A.; Mazina, K. E.; Holden, S. N.; Derynck, M. K.; De Bono, J. S.; Burris III, H. A. A first-inhuman, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumours or non-Hodgkin's lymphoma. J. Clin. Oncol. (ASCO Meeting Abstracts), 2010, 28, 3079.
121. Edelman, G.; Bedell, C.; Shapiro, G.; Pandya, S. S.; Kwak, E. L.; Scheffold, C.; Nguyen, L. T.; Laird, A.; Baselga, J. A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J. Clin. Oncol. (ASCO Meeting Abstracts), 2(SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. J. Clin. Oncol. (ASCO Meeting Abstracts), 2), 2010, 28, 3004.
122. Shapiro, G.; Kwak, E.; Baselga, J.; Rodon, J.; Scheffold, C.; Laird, A. D.; Bedell, C.; Edelman, G. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J. Clin. Oncol. (ASCO Meeting Abstracts), 2009, 27, 3500.
123. Herbst, R. S.; Falchook, G. S.; Messersmith, W. A.; Camidge, D. R.; Peterson, S. R.; Hausman, D. F.; Kurzrock, R.; Eckhardt, S. G.; Hong, D. S. A Phase I study of continuous dosing with PX-866 an irreversible pan-isoform inhibitor of PI3K. Eur. J. Cancer, 2010, 8, 366.
124. Brana, I.; LoRusso, P.; Baselga, J.; Heath, E. I.; Patnaik, A.; Gendreau, A. S.; Laird, A.; Papadopoulos K. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J. Clin. Oncol. (ASCO Meeting Abstracts), 2(SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J. Clin. Oncol. (ASCO Meeting Abstracts), 2), 2010, 28, 3030.
125. Nghiemphu, P. L.; Omuro, A. M.; Cloughesy, T.; Mellinghoff, I. K.; Norden, A. D.; Nguyen, L. T.; Rajangam, K.; Wen, P. Y. A phase I safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. J. Clin. Oncol. (ASCO Meeting Abstracts), 2(SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with newly diagnosed malignant glioma. J. Clin. Oncol. (ASCO Meeting Abstracts), 2), 2010, 28, 3085.
126. Cohen, R. B.; Janne, P. A.; Engelman, J. A.; Martínez, P.; Nishida, Y.; Gendreau, S.; Wu, B.; Felip, E. A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumours. J. Clin. Oncol. (ASCO Meeting Abstracts), 2(SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumours. J. Clin. Oncol. (ASCO Meeting Abstracts), 2), 2010, 28, 3015.
127. Furman, R.; Byrd, J. C.; Flinn, I. W.; Coutre, S. E.; Benson Jr., D. M.; Brown, J. R.; Kahl B. S.; Wagner-Johnston, N. D.; Giese, N. A.; Yu, A. S. Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J. Clin. Oncol. (ASCO Meeting Abstracts), 2010, 28, 3032.
128. Ellis, L. M.; Hicklin, D. J. Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology. Clin. Cancer Res., 2009, 15, 7471-7478.
129. Boyd, Z. S.; Wu, Q. J.; O'Brien, C.; Spoerke, J.; Savage, H.; Fielder, P. J.; Amler, L.; Yan, Y.; Lackner, M. R. Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol. Cancer Ther., 2008, 7, 3695-3706.
130. Dan, S.; Okamura, M.; Seki, M.; Yamazaki, K.; Sugita, H.; Okui, M.; Mukai, Y.; Nishimura, H.; Asaka, R.; Nomura, K.; Ishikawa, Y.; Yamori, T. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signalling pathway status: in silico and biological evaluations. Cancer Res., 2010, 70, 4982-4994.
131. Vasudevan, K. M.; Barbie, D. A.; Davies, M. A.; Rabinovsky, R.; McNear, C. J.; Kim, J. J.; Hennessy, B. T.; Tseng, H.; Pochanard, P.; Kim, S. Y.; Dunn, I. F.; Schinzel, A. C.; Sandy, P.; Hoersch, S.; Sheng, Q.; Gupta, P. B.; Boehm, J. S.; Reiling, J. H.; Silver, S.; Lu, Y.; Stemke-Hale, K.; Dutta, B.; Joy, C.; Sahin, A. A.; Gonzalez-Angulo, A. M.; Lluch, A.; Rameh, L. E.; Jacks, T.; Root, D. E.; Lander, E. S.; Mills, G. B.; Hahn, W. C.; Sellers, W. R.; Garraway, L. A. AKT-independent signalling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell, 2009, 16, 21-32.
132. Stemke-Hale, K.; Gonzalez-Angulo, A. M.; Lluch, A.; Neve, R. M.; Kuo, W. L.; Davies, M.; Carey, M.; Hu, Z.; Guan, Y.; Sahin, A.; Symmans, W. F.; Pusztai, L.; Nolden, L. K.; Horlings, H.; Berns, K.; Hung, M. C.; van de Vijver, M. J.; Valero, V.; Gray, J. W.; Bernards, R.; Mills, G. B.; Hennessy, B. T. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res., 2008, 68, 6084-6091.
133. Brachmann, S. M.; Hofmann, I.; Schnell, C.; Fritsch, C.; Wee, S.; Lane, H.; Wang, S.; Garcia-Echeverria, C.; Maira, S. M. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. USA, 2009, 106, 22299-22304.
134. O'Brien, C.; Wallin, J. J.; Sampath, D.; GuhaThakurta, D.; Savage, H.; Punnoose, E. A.; Guan, J.; Berry, L.; Prior, W. W.; Amler, L. C.; Belvin, M.; Friedman, L. S.; Lackner, M. R. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin. Cancer Res., 2010, 16, 3670-3683.
135. Ihle, N. T.; Lemos, R. Jr.; Wipf, P.; Yacoub, A.; Mitchell, C.; Siwak, D.; Mills, G. B.; Dent, P.; Kirkpatrick, D. L.; Powis, G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumour activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res., 2009, 69, 143-150.
136. Edgar, K. A.; Wallin, J. J.; Berry, M.; Lee, L. B.; Prior, W. W.; Sampath, D.; Friedman, L. S.; Belvin, M. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumours. Cancer Res., 2010, 70, 1164-1172.
137. Sos, M. L.; Fischer, S.; Ullrich, R.; Peifer, M.; Heuckmann, J. M.; Koker, M.; Heynck, S.; Stückrath, I.; Weiss, J.; Fischer, F.; Michel, K.; Goel, A.; Regales, L.; Politi, K. A.; Perera, S.; Getlik, M.; Heukamp, L. C.; Ansén, S.; Zander, T.; Beroukhim, R.; Kashkar, H.; Shokat, K. M.; Sellers, W. R.; Rauh, D.; Orr, C.; Hoeflich, K. P.; Friedman, L.; Wong, K. K.; Pao, W.; Thomas, R. K. Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer. Proc. Natl. Acad. Sci. USA, 2009, 106, 18351-18356.
138. Gupta, S.; Ramjaun, A. R.; Haiko, P.; Wang, Y.; Warne, P. H.; Nicke, B.; Nye, E.; Stamp, G.; Alitalo, K.; Downward, J. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumourigenesis in mice. Cell, 2007, 129, 957-968. (Pubitemid 46802703)
139. Engelman, J. A.; Chen, L.; Tan, X.; Crosby, K.; Guimaraes, A. R.; Upadhyay, R.; Maira, M.; McNamara, K.; Perera, S. A.; Song, Y.; Chirieac, L. R.; Kaur, R.; Lightbown, A.; Simendinger, J.; Li, T.; Padera, R. F.; García-Echeverría, C.; Weissleder, R.; Mahmood, U.; Cantley, L. C.; Wong, K. K. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med., 2008, 14, 1351-1356.
140. Faber, A. C.; Li, D.; Song, Y.; Liang, M. C.; Yeap, B. Y.; Bronson, R. T.; Lifshits, E.; Chen, Z.; Maira, S. M.; García-Echeverría, C.; Wong, K. K.; Engelman, J. A. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. USA, 2009, 106, 19503-19508.
141. Hammerman, P. S.; Janne, P. A.; Johnson, B. E. Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin. Cancer Res., 2009, 15, 7502-7509.
142. Milojkovic, D.; Apperley, J. Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia. Clin. Cancer Res., 2009, 15, 7519-7527.
143. Zunder, E. R.; Knight, Z. A.; Houseman, B. T.; Apsel, B.; Shokat, K. M. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell, 2008, 14, 180-192.
144. Yap, T. A.; Garrett, M. D.; Walton, M. I.; Raynaud, F.; de Bono, J. S.; Workman, P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls and promises. Curr. Opin. Pharmacol., 2008, 8, 393-412.
145. Schwertschlag, U. S.; Chiorean, E. G.; Anthony, S. P.; Sweeney, C. J.; Borad, M. J.; von Hoff, D. D.; Galrich, J. R.; Shelton, C. F.; Ramanathan, R. K. Phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of SF1126 a vascular targeted pan phosphoinositide 3-kinase (PI3K) inhibitor in patients with solid tumours. J. Clin. Oncol. (ACSO Meeting Abstracts), 2008, 26, 14532.
146. Chiorean, E. G.; Mahadevan, D.; Harris, W. B.; von Hoff, D. D.; Younger, A. E.; Rensvold, D. M.; Shelton, C. F.; Hennessy, B. T.; Garlich, J. R.; Ramanathan, R. K. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumours. J. Clin. Oncol. (ACSO Meeting Abstracts), 2009, 27, 2558.
147. Moldovan, C.; Soria, J.; LoRusso, P.; Guthrie, T.; Song, C.; Nguyen, L. T.; Martini, J.; Infante, J. R.; Burris III, H. A. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumours. J. Clin. Oncol. (ACSO Meeting Abstracts), 2(SAR245408) in combination with erlotinib in patients (pts) with advanced solid tumours. J. Clin. Oncol. (ACSO Meeting Abstracts), 2), 2010, 28, 3070.
148. Traynor, A. M.; Kurzrock, R.; Baley, H. H.; Attia, S.; Scheffold, C.; van Leeuwen, B.; Wu, B.; Falchook, G. S.; Moulder, S. L.; Wheler J. A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. J. Clin. Oncol. (ACSO Meeting Abstracts), 2(SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors. J. Clin. Oncol. (ACSO Meeting Abstracts), 2), 2010, 28, 3078.
149. Burris III, H.; Rodon, J.; Sharma, S.; Herbst, R. S.; Tabernero, J.; Infante, J. R.; Silva, A.; Demanse, D.; Hackl, W.; Baselga, J. First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumours. J. Clin. Oncol. (ACSO Meeting Abstracts), 2010, 28, 3005.
150. Britten, C. D.; Adjei, A. A.; Millham, R.; Houk, B.; Wainberg, Z. A.; Guthrie, T.; Dy, G.; Lo Russo, P. M. First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics. Eur. J. Cancer, 2010, 8, 383.
151. Shapiro, G. I.; Molina, J.; Bendell, J.; Braña, I.; Spicer, J.; Kwak, E.; Pandya, S.; Millham, R.; Houk, B.; Bell-McGuinn, K. First-in-human study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: preliminary report on safety and pharmacokinetics. Eur. J. Cancer, 2010, 8, 387.
152. Raynaud, F. I.; Eccles, S.; Clarke, P. A.; Hayes, A.; Nutley, B.; Alix, S.; Henley, A.; Di-Stefano, F.; Ahmad, Z.; Guillard, S.; Bjerke, L. M.; Kelland, L.; Valenti, M.; Patterson, L.; Gowan, S.; de Haven Brandon, A.; Hayakawa, M.; Kaizawa, H.; Koizumi, T.; Ohishi, T.; Patel, S.; Saghir, N.; Parker, P.; Waterfield, M.; Workman, P. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res., 2007, 67, 5840-5850. (Pubitemid 46985018)
153. Workman, P.; Collins, I. Probing the probes: fitness factors for small molecule tools. Chem. Biol, 2010, 17, 561-577.
154. Van Montfort, R. L.; Workman, P. Structure-based design of molecular cancer therapeutics. Trends Biotechnol, 2009, 27, 315-328.
155. Workman, P.; van Montfort, R. L. Unveiling the secrets of the ancestral PI3 kinase Vps34. Cancer Cell, 2010, 17, 421-423.
156. Workman, P.; van Montfort, L. PI (3) kinases: revealing the delta lady. Nat. Chem. Biol, 2010, 6, 82-83.
157. Jiang, X.; Chen, S.; Asara, J. M.; Balk, S. P. PI3K-Pathway Activation in PTEN Deficient Prostate Cancer Cells is Mediated by the p110β and p110δ Catalytic Subunits. J. Biol Chem., 2010, 285, 14980-14989.
158. Dbouk, H. A.; Pang, H.; Fiser, A.; Backer, J. M. A biochemical mechanism for the oncogenic potential of the p110β catalytic subunit of phosphoinositide-3 kinase. Proc. Natl Acad. Sci. USA, 2010, 107, 19897-19902.
159. Dbouk, H. A.; Backer, J. M. A beta version of life: p110β takes center stage. Oncotarget, 2010, 1, 729-733.
160. Shuttleworth, S. J.; Cecil, A. R. L.; Hill, T. J.; Silva, F. A. Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors. PCT Int. Pat, 2011, WO 2011/021038, February 24, 2011
161. Edling, C. E., Selvaggi, F.; Buus, R.; Maffucci, T.; Di Sebastiano, P.; Friess, H.; Innocenti, P.; Kocher, H. M,.; Falasca, M. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin. Cancer Res., 2010, 15, 4928-4937.